Research and publication ethics

  • HOME
  • Research and publication ethics
This academic journal follows and is published in accordance with the ethical guidelines described by the Good Publication Practice Guidelines for Medical Journals 3rd (Korean Association of Medical Journal Editors, KAMJE;, the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals ( from ICMJE, and the Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by COPE, DOAJ, WAME, and OASPA; The review and publication process are incorporated in the Council of Science Editors’s (CSE) Editorial Policy Statements (
1. Authorship and Contribution
1) Author’s qualifications
According to ICMJE guidelines, the authors of the paper must have the following criteria:
  • • Contributed to the creation of the basic concept or design of the study and the analysis or interpretation of the data.
  • • Written the manuscript, edited a major portion, or made a significant contribution that improved the content of the manuscript.
  • • Agreed to the contents of the final manuscript.
  • • Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
  • • The author list should include all appropriate researchers, and no others, who provide credit for a researcher’s contributions to a study and carries accountability.
2) Author contributions statements
Authors are required to include a statement of responsibility in the manuscript that specifies the contribution of every author at the end of the manuscript, in a section entitled “Author contributions,” including review-type articles. Any persons who do not meet the above four criteria may be listed as contributors in the Acknowledgments section.
3) Correction of authorship
After the initial submission of a manuscript, any changes in authorship (adding author(s), deleting author(s), or rearranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. dmj does not correct authorship after publication unless a mistake has been made by the editorial staff.
2. Disclosure of Conflict of Interest
dmj requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a Conflict of Interest section at the end of the manuscript listing all competing interests (financial and nonfinancial). Financial relationships, such as employment, consultancies, stock ownership, honoraria, and paid expert testimony, are the most easily identifiable conflicts of interest. However, conflicts can occur for other reasons as well, such as personal relationships, academic competition, and intellectual passion ( Where authors have no competing interests, the statement should read “The author(s) declares that he/she(they) has(have) no competing interests.” If the study was sponsored by a third party, authors should describe the role of the study sponsor in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. If the supporting source had no such involvement, the authors should so state.
3. Statement of Human and Animal Rights
All studies performed on humans must comply with the principles laid down in the Declaration of Helsinki, “Recommendations guiding physicians in biomedical research involving human subjects,” adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964 (and successive amendments). Studies involving experiments with animals must state that their care was in accordance with national laws and institutional regulations. The ethical treatment of all experimental animals must conform to the guidelines provided by the Institutional Animal Care and Use Committee (IACUC). The experiment plans approved by the experimental animal ethics committee must be available for submission upon request when deemed necessary by the editors or reviewers.
4. Statement of Informed Consent and Institutional Review Board Approval
Research involving human subjects, human material, or human data must have been approved by an appropriate ethics committee. A statement about this, including the name of the ethics committee and the reference number, must appear in all manuscripts reporting such research. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption). In the process of submitting the manuscript, the IRB approval document must be loaded. For all research involving human subjects, informed consent to participate in the study should be obtained from participants, and a statement to this effect should appear in the manuscript.
5. Registration of Clinical Trial Research
We recommend, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as studies on pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt. Registries include: (1) the registry sponsored by the United States National Library of Medicine (; (2) the International Standard Randomized Controlled Trial Number Registry (; (3) the Australian New Zealand Clinical Trials Registry (; (4) the Chinese Clinical Trials Register (; (5) the Clinical Trials Registry-India (; (6) University Hospital Medical Information Network (UMIN) (; and (7) the Clinical Research Information Service-South Korea ( Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement:
6. Originality and Duplicate Publication
The submitted manuscripts must be original. The manuscript may not be considered for publication in another magazine or journal. Additionally, no part of the manuscript may be published elsewhere without permission from the editorial board. In the event that a publishing violation has occurred, the journal will be notified, the offenders may be penalized, and the institutions affiliated with the authors will be notified.
7. Process to Manage the Research and Publication Misconduct
dmj is a member of Cross-Check’s plagiarism detection initiative and takes all cases of publication misconduct seriously. If the dmj staff discover suspected cases of research and publication misconduct, such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, and an ethical problem, the resolution process will follow the flowchart provided by the Committee on Publication Ethics ( All reviewers have a responsibility to report any suspected issues with the manuscript to the editor. If the investigation proves scientific misconduct, a retraction of the article will be published. If warranted, the authors will be invited to prepare the retraction, which should be submitted with an assignment of copyright statement that has been signed by all authors. If the paper has not been published, then the editor can always reject the paper. Instances of misconduct in the publication process will be shared with the editorial board of the dmj. The editor may wish to impose sanctions, notify editors of other biomedical journals, and depending on the severity of the allegation, notify the author’s institution. dmj will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when the misconduct is founded.
8. Clinical Data-Sharing Policy
dmj recommends that all submitted manuscripts that report the results of clinical trials should adhere to the Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors (;
9. Secondary Publication
It is possible to republish manuscripts if the manuscripts satisfy the condition of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by the International Committee of Medical Journal Editors (ICMJE, as follows:
  • • The authors have received approval from the editors of both journals (the editor concerned with the secondary publication must have access to the primary version).
  • • The priority for the primary publication is respected by a publication interval negotiated by editors of both journals and the authors.
  • • The paper for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient.
  • • The secondary version faithfully reflects the data and interpretations of the primary version.
  • • The secondary version informs readers, peers, and documenting agencies that the paper has been published in whole or in part elsewhere—for example, with a note that might read, “This article is based on a study first reported in the [journal title, with full reference]”—and the secondary version cites the primary reference.
  • • The title of the secondary publication should indicate that it is a secondary publication (complete or abridged republication or translation) of a primary publication. Of note, the United States National Library of Medicine (NLM) does not consider translations to be “republications” and does not cite or index them when the original article was published in a journal that is indexed in MEDLINE.

Diabetes &

Print ISSN: 2233-6079
Online ISSN: 2233-6087

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail:                

Copyright © 2020 by Korean Diabetes Association. All rights reserved.

Developed in M2community

Close layer